The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Updates on the TELLOMAK trial
Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, shares early findings from the Phase II TELLOMAK trial (NCT03902184) evaluating the efficacy of lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemotherapy in patients with advanced cutaneous T-cell lymphoma (CTCL). During the EORTC CL group meeting, Dr Bagot presented promising skin results and a tolerable safety profile for cohorts 2 (KIR3DL2 expressing) and 3 (KIR3DL2 non-expressing), both composed of patients with mycosis fungoides (MF). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
